Hot Pharma Stocks / Ideen / Blockbuster

    OREX hat nächsten Montag PDUFA. Es könnte sein, dass bei OREX schon früher was losgeht. Ich möchte erwähnen, dass wenn OREX einen positiven Entscheid für die fat-burner Pille bekommen würde, dass es dann mächtig in die Höhe schiessen könnte. Ich spreche hier von einer Mrkt. Kapitalisierung von ca. 1.5- 5 Milliarden US-Dollar.

    Wer nach vorne schauen will, muss erst mal zurück schauen:



    External Content www.youtube.com
    Content embedded from external sources will not be displayed without your consent.
    Through the activation of external content, you agree that personal data may be transferred to third party platforms. We have provided more information on this in our privacy policy.

    Hot Pharma Stocks / Ideen / Blockbuster

    sharewatch wrote:

    Quote
    ist das was?

    http://www.google.com/finance?q=rtix


    TSRX gefällt mir besser. Chart sieht nicht schlecht aus und Pipeline könnte was hergeben.

    Wer nach vorne schauen will, muss erst mal zurück schauen:



    External Content www.youtube.com
    Content embedded from external sources will not be displayed without your consent.
    Through the activation of external content, you agree that personal data may be transferred to third party platforms. We have provided more information on this in our privacy policy.

    DEPO scheint mir wie schon davor, das Gap zu schliessen. 6.50 USD oder sogar 7 USD sollten bis Donnerstag Abend drin sein. Wer sich eine Posi gönnt, soll sich mit einem Stop Loss absichern.


    Der Chart von heute zeigt grobe Widerstände nach unten. bzw. die Aktie sieht stark bullish aus.

    Wer nach vorne schauen will, muss erst mal zurück schauen:



    External Content www.youtube.com
    Content embedded from external sources will not be displayed without your consent.
    Through the activation of external content, you agree that personal data may be transferred to third party platforms. We have provided more information on this in our privacy policy.

    Re: DEPO

    equity holder wrote:

    Quote
    DEPO scheint mir wie schon davor, das Gap zu schliessen. 6.50 USD oder sogar 7 USD sollten bis Donnerstag Abend drin sein. Wer sich eine Posi gönnt, soll sich mit einem Stop Loss absichern.

    Der Chart von heute zeigt grobe Widerstände nach unten. bzw. die Aktie sieht stark bullish aus.


    wenn man so rum googelt, dann liest man immer wieder, dass der FDA entscheid morgen oder auch donnerstag schon kommen kann. mich hats auch schon so erwischt, dass der FDA entscheid vor dem angekündigte termin kam.

    Re: DEPO

    Per wrote:

    Quote

    equity holder wrote:


    wenn man so rum googelt, dann liest man immer wieder, dass der FDA entscheid morgen oder auch donnerstag schon kommen kann. mich hats auch schon so erwischt, dass der FDA entscheid vor dem angekündigte termin kam.




    Ja, kann mich noch gut erinnern, als es Dich erwischte. Nur, dass bei DEPO die Chancen für die Zulassung gemäss recherche gut sind.


    Jedenfalls ist der FDA Termin auf Sonntag vorgesehen. Und ich kann mir relativ gut vorstellen, dass er am Freitag stattfinden wird. Donnerstag wäre auch möglich. Merci, für die Warnung, an Donnerstag habe ich gar nicht gedacht. (Ich schliesse es mal mit ein.)


    Meine Top-Titel für diese Woche sind OREX und DEPO. DEPO habe ich lediglich, wegen dem Crash. Ich habe das Teil sauber geshortet und gleich eingekauft. Das Gap-Close ist rein vom Marktverhalten vor dem FDA Termin gegeben.

    Wer nach vorne schauen will, muss erst mal zurück schauen:



    External Content www.youtube.com
    Content embedded from external sources will not be displayed without your consent.
    Through the activation of external content, you agree that personal data may be transferred to third party platforms. We have provided more information on this in our privacy policy.

    Re: DEPO

    Per wrote:

    Quote
    ich glau ich halt wieder mal durch den entscheid :roll:


    Schön dass Jemand davon profitieren kann. Nun, wie gesagt, ich werde die Titel spätestens Donnerstag Abend komplett verkaufen. Durch den FDA Entscheid würde ich nicht, da sich der Preis der Aktie seit August mehr als verdoppelt hat. Ich würde jetzt nicht durch den FDA Entscheid gehen. Wenn es eine Kursmanipulation gibt, dann gehe ich durch den FDA Entscheid am Freitag. Versprechen kann ich nichts, ich erwähne nur, dass ich einen bear raid für möglich halte.

    Wer nach vorne schauen will, muss erst mal zurück schauen:



    External Content www.youtube.com
    Content embedded from external sources will not be displayed without your consent.
    Through the activation of external content, you agree that personal data may be transferred to third party platforms. We have provided more information on this in our privacy policy.

    Hot Pharma Stocks / Ideen / Blockbuster

    Für alle Celldex-Beobachter!


    Meiner Meinung nach gerade beste Einsteigekurse! Der Preis und das Sentiment (siehe Yahoo-Message board) sind absolut am Boden.


    Events kommen! Hab ein Mail von SVP/CFO Chip Catlin:


    "Dr. Schneeberger,


    We were at the JPMorgan conference in San Francisco earlier this month but we were not invited to present like most small cap biotechs. We did have a number of successful one-on-one meetings with investors and potential investors.


    We have a meeting scheduled with the FDA next month at which we will review the rindopepimut phase 3 clinical study design and protocol. After those conversations with the FDA are concluded we will be able to provide color to our investors about the finalized clinical study design, including the number of subjects in the study. We will communicate with investors as soon as possible.


    We will be releasing our year-end earnings during the first week of March.


    We plan on attending this year's ASCO meeting.


    Chip Catlin"


    Bin mir fast sicher, dass bis in 6 Wochen die Aktie die 5$ Marke zumindest wieder mal küsst!

    RPC

    Early reaction to Radient Pharmaceuticals' news



    Written by Staff and Wire Reports

    Wednesday, 26 January 2011 20:42


    Shares of Radient Pharmaceuticals (Amex:RPC) traded down in panic after the company released news that officials at the American Stock Exchange had sent a notice dated January 25, 2010 advising them that as of that date, RPC remained non-compliant with listing standards.


    We immediately contacted officials at the company and others who have explained the situation to us and we will be publishing a special report across the wires based our findings in the morning. In the meantime, there are some key takeways:


    1- The decision to issue the delisting notice came after an official at the Exchange reviewed the company's filings as of the third quarter of 2010 (that is the latest public filing available).


    2- The analysis by the Exchange official was based on pre debt-to-equity numbers and balance sheets.


    3- Key investors, management and financeers involved with RPC and their soon to be announced public spin-offs all told us that they continue to believe in the Company more than ever and that the issue will be resolved and likely become a "non-event" given that Radient is in a very different position (financially and otherwise) than it was during the, now dated, snapshot analysis.


    4- After much back and forth debate during the past 24 hours, attorneys advised the company to put out the press release as issued in order to satisfy various legal requirements and disclosures- despite the fact that many within the organization felt the wording was too strong and negative given the current events and financial developments.


    5- The company is in the middle of several key developments which were previusly disclosed and are set to be finalized in the coming days. Those material events will unequivocally and unmistakably add more value and equity to the stock.


    6- Our fact based report and analysis of the news will be published tomorrow and we have also scheduled an interview with CEO, Douglas MacLellan in order to give him the opportunity to address shareholders.


    Every person we spoke to, including several key investors who are involved in the re-structuring and public spin-offs at Radient came across to us very confident each one seperately told us that they are, obviously, putting their money where their mouth is by moving forward with all plans and investments.


    Unfortunately, this type of panic sets in when investors do not have enough information to make clear decisions. We intend to provide the facts as objectively as possible as we are presented with them. Once we speak to Mr. MacClellan, he will undoubtedly add even more clairty and we will publish his comments as soon as we have them.


    As professional traders know and we saw with Intellipharmaceutics (NASDAQ:IPCI), another company which we have been covering the past two weeks, the big boards (exchanges) often issue de-listing notices. IPCI announced Wednesday afternoon that they had regained NASDAQ Compliance after facing months of negative speculation a positive developments themselves. If these companies were over-the-counter stocks, they would not be dealing with these issues, but that is why speculators and investors feel more security transacting on these exchanges.


    Remember that what publications report and officials say on the record during critical times like these is reviewed by securites officials at multiple agencies and exchanges. As always, we will do our best to help communicate the facts to our readers and subscribers so that they can make the best investment decisions possible given the intelligence we are able to gather.


    Developing...